| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
IC50: 90 nM (PTHR1)[1]
DS08210767 targets the parathyroid hormone type 1 receptor (PTHR1). As an antagonist, it binds to PTHR1 and inhibits its activity. PTHR1 is a G protein-coupled receptor that plays a critical role in calcium homeostasis and bone metabolism. By inhibiting PTHR1, the compound modulates parathyroid hormone signaling pathways. The compound shows an IC₅₀ of 90 nM. It is used in biochemical and pharmacological research to better understand disease mechanisms. |
|---|---|
| ln Vitro |
In vitro, DS08210767 demonstrates potent PTHR1 antagonism with an IC₅₀ of 90 nM. This value indicates its high potency in inhibiting PTHR1-mediated signaling. The compound is used in cell-based assays to investigate its effects on PTHR1 signaling pathways. Its potency makes it suitable for studying calcium homeostasis, bone metabolism, and related disorders. The compound is supplied for research purposes only. Specific assay details are not detailed in the available sources.
|
| ln Vivo |
In vivo, DS08210767 is orally bioavailable, indicating that it can be administered orally and maintain its biological activity. It is used in preclinical studies to investigate its effects on PTHR1-mediated physiological processes. Its oral bioavailability makes it suitable for in vivo efficacy studies in animal models of diseases related to PTHR1 signaling. Specific in vivo efficacy data are not detailed in the available sources.
|
| Enzyme Assay |
Non-cell-based enzyme/receptor binding assays for DS08210767 typically involve competitive binding studies using purified PTHR1 protein or membrane preparations from cells expressing PTHR1. Standard protocols include incubating varying concentrations of the test compound with the receptor and a radiolabeled PTH ligand in appropriate buffer systems, followed by separation of bound from free ligand via filtration or centrifugation. Binding affinity (IC₅₀ values) is calculated using nonlinear regression analysis. The compound shows an IC₅₀ of 90 nM. Surface plasmon resonance (SPR) may also be employed.
|
| Cell Assay |
Cell-based assays for DS08210767 typically utilize cell lines expressing PTHR1 and a reporter gene (e.g., CRE-luciferase) to measure PTH-induced signaling. Standard protocols involve culturing cells in appropriate media at 37°C in 5% CO₂, followed by treatment with varying concentrations of the compound (typically 0.01-10 μM) and PTH peptide for 4-6 hours. Reporter gene activity is quantified by luminescence. IC₅₀ values are calculated from dose-response curves. The compound's ability to inhibit PTH-induced signaling is assessed.
|
| Animal Protocol |
In vivo animal studies for DS08210767 typically involve oral administration in rodent models (mice or rats). Standard protocols include dosing at ranges of 1-50 mg/kg body weight, with observations over 7-14 days depending on the study objectives. Pharmacodynamic assessments may include blood sampling for calcium and PTH levels, bone density measurements, and monitoring of body weight and general health parameters. All animal studies must comply with institutional ethical guidelines. Specific efficacy data are not detailed in the available sources.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties for DS08210767 are characterized by oral bioavailability. The compound has a molecular weight of 513.67 g/mol and shows solubility in DMSO (5 mg/mL). It should be stored at -20°C and is stable for ≥2 years. For in vivo administration, formulations using suitable co-solvent systems may be employed. Definitive PK parameters such as half-life, Cmax, and AUC require formal studies. The compound is supplied for research purposes only.
|
| References | |
| Additional Infomation |
DS08210767 is a highly potent, orally bioavailable PTHR1 antagonist with an IC₅₀ of 90 nM. It is a novel, small-molecule 1,4-benzodiazepin-2-one derivative. The compound is used in biochemical and pharmacological research to study PTHR1 signaling pathways and disease mechanisms. It is not an approved drug and has not undergone clinical trials; it is strictly for research purposes.
|
| Molecular Formula |
C31H39N5O2
|
|---|---|
| Molecular Weight |
513.673667192459
|
| Exact Mass |
513.31
|
| CAS # |
2376334-75-5
|
| PubChem CID |
139035050
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
4.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
38
|
| Complexity |
874
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1CCC(CC1)NCCNC1C=CC(=CC=1)N1C(C(C)(C)N=C(C2C=CC(C#N)=CC1=2)C1CCCCC1)=O
|
| InChi Key |
SOYFWNNFRLABJC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C31H39N5O2/c1-31(2)30(37)36(26-11-9-24(10-12-26)33-16-17-34-25-14-18-38-19-15-25)28-20-22(21-32)8-13-27(28)29(35-31)23-6-4-3-5-7-23/h8-13,20,23,25,33-34H,3-7,14-19H2,1-2H3
|
| Chemical Name |
5-cyclohexyl-3,3-dimethyl-1-[4-[2-(oxan-4-ylamino)ethylamino]phenyl]-2-oxo-1,4-benzodiazepine-8-carbonitrile
|
| Synonyms |
DS08210767; 2376334-75-5; CHEMBL4465123; 5-Cyclohexyl-2,3-dihydro-3,3-dimethyl-2-oxo-1-[4-[[2-[(tetrahydro-2H-pyran-4-yl)amino]ethyl]amino]phenyl]-1H-1,4-benzodiazepine-8-carbonitrile; 5-Cyclohexyl-3,3-dimethyl-1-[4-[2-(oxan-4-ylamino)ethylamino]phenyl]-2-oxo-1,4-benzodiazepine-8-carbonitrile;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 5 mg/mL (9.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9468 mL | 9.7339 mL | 19.4678 mL | |
| 5 mM | 0.3894 mL | 1.9468 mL | 3.8936 mL | |
| 10 mM | 0.1947 mL | 0.9734 mL | 1.9468 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
